News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Covidien plc (COV) Announces Five-Year Results From the ClosureFast™ Long-Term European Multi-Center Study in Patients With Lower Limb Venous Disease


12/20/2012 8:52:05 AM

MANSFIELD, Mass.--(BUSINESS WIRE)--Covidien (NYSE:COV), a leading global provider of healthcare products, today announced the five-year results of the ClosureFastâ„¢ Long-Term European Multi-Center Study in patients with Chronic Venous Insufficiency (CVI). This study evaluates the five-year outcomes of a minimally invasive endovascular therapy for treatment of CVI. The ClosureFast Study was conducted prospectively at eight centers in Europe. The Venefitâ„¢ procedure (using the ClosureFast radiofrequency ablation catheter) was used to treat 295 lower limbs in 225 patients diagnosed with superficial venous reflux, the underlying cause of varicose veins and CVI. This progressive medical condition affects the veins in the leg and compromises their ability to carry blood back to the heart. This is a worldwide issue and, in fact, impacts over 30 million Americans in the United States alone.1 If left untreated, varicose veins can advance to CVI, which, in severe cases, may result in lower leg pain, skin damage, and leg ulcerations.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES